In this Phase 2a, multi-center, open label, proof-of-biology study, ANX005 will be administered to participants with ALS.~The study consists of approximately 22 weeks of treatment and approximately 14 weeks of follow-up. All participants will be contacted by phone 6 months after study completion.
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.